ReviewEuropean journal of nuclear medicine and molecular imaging2018
Correlation of dose with toxicity and tumour response to
Review in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 145 citations in OpenAlex.
- Dosimetry of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-basedEuropean journal of nuclear medicine and molecular imaging · 2022Trial
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- Emerging need of dosimetry in radioligand therapy: a feasible method tested in a large cohort of patients affected by neuroendocrine neoplasms.EJNMMI research · 2026Article
- Inter-institutional variability in kidney dosimetry duringRadiological physics and technology · 2026Article
- Safety and efficacy of peptide receptor radionuclide therapy for advanced medullary thyroid cancer: a systematic review and meta-analysis.Thyroid research · 2026Review
- Article
- Impact of extended [European journal of nuclear medicine and molecular imaging · 2025Article
- CanJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Multicycle Dosimetric Behavior and Dose-Effect Relationships in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry inMolecular imaging and biology · 2025Article
- Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours.Journal of neuroendocrinology · 2025Review
- An overview of the role of radionuclides in targeted cancer treatment: application of biomarkers for patient selection and developments to improve treatment efficacy.Frontiers in oncology · 2025Review
- Do we need dosimetry for the optimization of theranostics in CNS tumors?Neuro-oncology · 2024Review
- Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers.Journal of cancer research and clinical oncology · 2024Article
- Heterogeneity of absorbed dose distribution in kidney tissues and dose-response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review.Zeitschrift fur medizinische Physik · 2024Review
- Impact of the Reference Multiple-Time-Point Dosimetry Protocol on the Validity of Single-Time-Point Dosimetry for [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?EJNMMI physics · 2024Review
- Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
Abstract
purposePeptide receptor radionuclide therapy (PRRT) with
methodsThe MEDLINE database was searched combining specific keywords. Original studies published in the English language reporting dose-effect outcomes in patients treated with PRRT were chosen.
resultsNine of 126 studies were selected from PubMed, and a further five were added manually, reporting on 590 patients. The studies were analysed and are discussed in terms of weak and strong elements of correlations.
conclusionSeveral studies provided evidence of clinical benefit from the implementation of dosimetry in PRRT, indicating the potential contribution of this approach to reducing severe toxicity and/or reducing undertreatment that commonly occurs. Prospective trials, possibly multicentre, with larger numbers of patients undergoing quantitative dosimetry and with standardized methodologies should be carried out to definitively provide robust predictive paradigms to establish effective tailored PRRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.